News
CRIS
3.243
+2.29%
0.073
Weekly Report: what happened at CRIS last week (1216-1220)?
Weekly Report · 3d ago
Weekly Report: what happened at CRIS last week (1209-1213)?
Weekly Report · 12/16 12:21
Curis Price Target Maintained With a $20.00/Share by HC Wainwright & Co.
Dow Jones · 12/10 17:31
HC Wainwright & Co. Reiterates Buy on Curis, Maintains $20 Price Target
Benzinga · 12/10 17:20
Promising Clinical Trial Results and Robust Financial Projections Drive Buy Rating for Emavusertib
TipRanks · 12/10 16:05
CURIS ANNOUNCES ADDITIONAL DATA FROM TAKEAIM LEUKEMIA STUDY
Reuters · 12/10 13:00
Weekly Report: what happened at CRIS last week (1202-1206)?
Weekly Report · 12/09 12:20
Curis granted FDA orphan designation for emavusertib
TipRanks · 12/04 00:00
Weekly Report: what happened at CRIS last week (1125-1129)?
Weekly Report · 12/02 12:20
Weekly Report: what happened at CRIS last week (1118-1122)?
Weekly Report · 11/25 12:08
Weekly Report: what happened at CRIS last week (1111-1115)?
Weekly Report · 11/18 12:04
Curis Inc. Receives Buy Rating: Strong Financials and Promising Clinical Trial Progress Drive Growth Potential
TipRanks · 11/15 11:27
Curis Inc. Reports Positive Q3 2024 Earnings
TipRanks · 11/15 04:00
Based on the provided financial report, the title of the article is: "CURIS, INC. AND SUBSIDIARIES QUARTERLY REPORT ON FORM 10-Q
Press release · 11/14 21:28
Curis (CRIS) Reports Q3 Loss, Tops Revenue Estimates
NASDAQ · 11/14 14:10
Curis reports Q3 EPS ($1.70), consensus ( $1.88)
TipRanks · 11/14 13:15
Curis sees cash and cash equivalents sufficient into mid-2025
TipRanks · 11/14 13:14
Curis Inc Q3 Loss Decreases, Beats Estimates
NASDAQ · 11/14 13:09
Curis Q3 2024 GAAP EPS $(1.70) Beats $(1.83) Estimate, Cash And Cash Equivalents Of $31.6M Is Expected To Provide Cash Runway Into Mid-2025
Benzinga · 11/14 13:08
*Curis 3Q Rev $2.93M >CRIS
Dow Jones · 11/14 13:05
More
Webull provides a variety of real-time CRIS stock news. You can receive the latest news about Curis through multiple platforms. This information may help you make smarter investment decisions.
About CRIS
Curis, Inc. is a biotechnology company. The Company is focused on the development of emavusertib (CA-4948), an orally available, small molecule inhibitor of Interleukin-1 receptor associated kinase (IRAK4). Emavusertib is undergoing testing in the Phase I/II TakeAim Lymphoma study in patients with relapsed/refractory primary central nervous system lymphoma (PCNSL) in combination with the BTK inhibitor ibrutinib, as a monotherapy in the Phase I/II TakeAim Leukemia study in patients with relapsed/refractory acute myeloid leukemia (AML) and relapsed/refractory high risk myelodysplastic syndrome (hrMDS). Its other clinical programs include Fimepinostat and CA-170. Fimepinostat is an oral, dual inhibitor of histone deacetylase (HDAC), and phosphotidyl-inositol 3 kinase (PI3K) enzymes. CA-170 is an oral small molecule drug candidate that is designed to selectively target V-domain Ig Suppressor of T-cell Activation (VISTA) and PDL1 immune checkpoint proteins.